Skip to main content
Clinical Trials/NCT02308787
NCT02308787
Completed
Not Applicable

Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for Platelet Depletion Procedures.

Terumo BCT2 sites in 2 countries12 target enrollmentNovember 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Thrombocythemia
Sponsor
Terumo BCT
Enrollment
12
Locations
2
Primary Endpoint
Percent Change in Platelet (PLT) Count in Patient Blood Following Apheresis Procedure
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Multicenter, Retrospective Data Collection of Routine Clinical Use with the Spectra Optia® Apheresis System for Platelet Depletion Procedures.

Detailed Description

This is a multicenter, retrospective data collection to evaluate the in routine use performance and safety of platelet depletions performed via the Spectra Optia system. Data collection will include procedures in 2- 3 different centers in Europe done between November 2011 and April 2014.

Registry
clinicaltrials.gov
Start Date
November 2014
End Date
May 2015
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Terumo BCT
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients having received a minimum of one platelet depletion procedure via the Spectra Optia system.
  • Availability of complete blood count results prior to starting and after completing the platelet depletion procedure via the Spectra Optia system.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Percent Change in Platelet (PLT) Count in Patient Blood Following Apheresis Procedure

Time Frame: on average this will be within 15 minutes after the end of the procedure

(PLTpre - PLTpost) / PLTpre x 100%

Percent of Processed Platelets (PLT) Which Are Collected i.e. Collection Efficiency for Platelets Achieved by Spectra Optia.

Time Frame: on average this will be within 15 minutes after the end of the procedure

(PLT/µL product x product volume) / ((PLTpre + PLTpost) / 2) x total processed blood volume)

Adverse Events

Time Frame: during the apheresis procedure (from the moment the patient is connected until he is disconnected from the device) and device or procedure related adverse events until discharge from Apheresis Unit (On average, half hour after end of procedure).

Study Sites (2)

Loading locations...

Similar Trials